Alpha-1-adrenergic receptors: Targets for agonist drugs to treat heart failure

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 518-528

  Jensen, Brian C ^a,c,d   O'Connell, Timothy D ^e   Simpson, Paul C ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Alpha 1 Adrenergic receptors; Cardiac myocytes; Drug development; Heart failure

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; CARVEDILOL; DOXAZOSIN; MOXONIDINE; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; NORADRENALIN; PHENTOLAMINE; PRAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ALPHA ADRENERGIC STIMULATION; APOPTOSIS; BLOOD PRESSURE REGULATION; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INOTROPISM; INTRACELLULAR SIGNALING; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; TISSUE DISTRIBUTION;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; HEART; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIUM; RECEPTORS, ADRENERGIC, ALPHA-1; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA;

EID: 80052787583     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.11.014     Document Type: Review

References (216)

1. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984 Sep 27, 311(13):819-823.
2. Mann D.L., Kent R.L., Parsons B., Cooper Gt. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992 Feb, 85(2):790-804.
3. Communal C., Singh K., Pimentel D.R., Colucci W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998 Sep 29, 98(13):1329-1334.
4. Iwai-Kanai E., Hasegawa K., Araki M., Kakita T., Morimoto T., Sasayama S. alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 1999 Jul 20, 100(3):305-311.
5. Engelhardt S., Hein L., Wiesmann F., Lohse M.J. Progressive hypertrophy and heart failure in beta(1)-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999, 96(12):7059-7064.
6. Bisognano J.D., Weinberger H.D., Bohlmeyer T.J., Pende A., Raynolds M.V., Sastravaha A., et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000, 32(5):817-830.
7. Lohse M.J., Engelhardt S., Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 2003 Nov 14, 93(10):896-906.
8. Zhu W.Z., Wang S.Q., Chakir K., Yang D., Zhang T., Brown J.H., et al. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 2003 Mar, 111(5):617-625.
9. Triposkiadis F., Karayannis G., Giamouzis G., Skoularigis J., Louridas G., Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009 Nov 3, 54(19):1747-1762.
10. Xydas S., Kherani A.R., Chang J.S., Klotz S., Hay I., Mutrie C.J., et al. beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy. J Pharmacol Exp Ther 2006 May, 317(2):553-561.
11. Ahmet I., Morrell C., Lakatta E.G., Talan M.I. Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 2009 Oct, 331(1):178-185.
12. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 Apr 14, 119(14):e391-e479.
13. Graham R.M., Perez D.M., Hwa J., Piascik M.T. alpha 1-Adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ Res 1996 May, 78(5):737-749.
14. Zhong H., Minneman K.P. Alpha1-adrenoceptor subtypes. Eur J Pharmacol 1999 Jun 30, 375(1-3):261-276.
15. Piascik M.T., Perez D.M. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 2001 Aug, 298(2):403-410.
16. Simpson P. Lessons from knockouts: the alpha1-ARs. The Adrenergic Receptors in the 21st Century 2006, 207-240. Humana Press, Totowa, New Jersey. D.M. Perez (Ed.).
17. Hein P., Michel M.C. Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal?. Biochem Pharmacol 2007 Apr 15, 73(8):1097-1106.
18. Bylund D.B., Bond R.A., Eikenburg D.C., Hieble J.P., Hills R., Minneman K.P., et al. Adrenoceptors: IUPHAR database (IUPHAR-DB) Last modified on 2010-07-21. http://wwwiuphar-dborg/DATABASE/FamilyMenuForward?familyId=4.
19. Zhu F., Han L., Zheng C., Xie B., Tammi M.T., Yang S., et al. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets. J Pharmacol Exp Ther 2009 Jul, 330(1):304-315.
20. Steinberg S.F., Drugge E.D., Bilezikian J.P., Robinson R.B. Acquisition by innervated cardiac myocytes of a pertussis toxin-specific regulatory protein linked to the alpha 1-receptor. Science 1985 Oct 11, 230(4722):186-188.
21. Hu K., Nattel S. Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Circulation 1995 Oct 15, 92(8):2259-2265.
22. Akhter S.A., Milano C.A., Shotwell K.F., Cho M.C., Rockman H.A., Lefkowitz R.J., et al. Transgenic mice with cardiac overexpression of a1B-adrenergic receptors. In vivo a1-adrenergic receptor-mediated regulation of b-adrenergic signaling. J Biol Chem 1997, 272(34):21253-21259.
23. Melien O., Sandnes D., Johansen E.J., Christoffersen T. Effects of pertussis toxin on extracellular signal-regulated kinase activation in hepatocytes by hormones and receptor-independent agents: evidence suggesting a stimulatory role of G(i) proteins at a level distal to receptor coupling. J Cell Physiol 2000 Jul, 184(1):27-36.
24. Snabaitis A.K., Muntendorf A., Wieland T., Avkiran M. Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of G(q/11), Gi and G(12/13) proteins in signalling by alpha1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors. Cell Signal 2005 May, 17(5):655-664.
25. O'Connell T.D., Ishizaka S., Nakamura A., Swigart P.M., Rodrigo M.C., Simpson G.L., et al. The a1A/C- and a1B-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest 2003 Jun, 111(11):1783-1791.
26. O'Connell T.D., Swigart P.M., Rodrigo M.C., Ishizaka S., Joho S., Turnbull L., et al. Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 2006 Apr, 116(4):1005-1015.
27. Huang Y., Wright C.D., Merkwan C.L., Baye N.L., Liang Q., Simpson P.C., et al. An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation 2007 Feb 13, 115(6):763-772.
28. Benfey B.G. Function of myocardial alpha-adrenoceptors. Life Sci 1990, 46(11):743-757.
29. Li K., He H., Li C., Sirois P., Rouleau J.L. Myocardial alpha1-adrenoceptor: inotropic effect and physiologic and pathologic implications. Life Sci 1997, 60(16):1305-1318.
30. Salvi S. Protecting the myocardium from ischemic injury: a critical role for alpha(1)-adrenoreceptors?. Chest 2001 Apr, 119(4):1242-1249.
31. Mani K., Ashton A.W., Kitsis R.N. Taking the BAD out of adrenergic stimulation. J Mol Cell Cardiol 2002 Jul, 34(7):709-712.
32. Woodcock E.A., Du X.J., Reichelt M.E., Graham R.M. Cardiac alpha 1-adrenergic drive in pathological remodelling. Cardiovasc Res 2008 Feb 1, 77(3):452-462.
33. Gottlieb S.S. The neurohormonal paradigm: have we gone too far?. J Am Coll Cardiol 2003 May 7, 41(9):1458-1459.
34. Mehra M.R., Uber P.A., Francis G.S. Heart failure therapy at a crossroad: are there limits to the neurohormonal model?. J Am Coll Cardiol 2003 May 7, 41(9):1606-1610.
35. Steinfath M., Chen Y.Y., Lavicky J., Magnussen O., Nose M., Rosswag S., et al. Cardiac alpha 1-adrenoceptor densities in different mammalian species. Br J Pharmacol 1992 Sep, 107(1):185-188.
36. Turnbull L., McCloskey D.T., O'Connell T.D., Simpson P.C., Baker A.J. Alpha 1-adrenergic receptor responses in alpha 1AB-AR knockout mouse hearts suggest the presence of alpha 1D-AR. Am J Physiol Heart Circ Physiol 2003 Apr, 284(4):H1104-H1109.
37. Chalothorn D., McCune D.F., Edelmann S.E., Tobita K., Keller B.B., Lasley R.D., et al. Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes. J Pharmacol Exp Ther 2003 Jun, 305(3):1045-1053.
38. Stewart A.F., Rokosh D.G., Bailey B.A., Karns L.R., Chang K.C., Long C.S., et al. Cloning of the rat alpha 1C-adrenergic receptor from cardiac myocytes. alpha 1C, alpha 1B, and alpha 1D mRNAs are present in cardiac myocytes but not in cardiac fibroblasts. Circ Res 1994 Oct, 75(4):796-802.
39. Marino T.A., Cassidy M., Marino D.R., Carson N.L., Houser S. Norepinephrine-induced cardiac hypertrophy of the cat heart. Anat Rec 1991 Apr, 229(4):505-510.
40. Benjamin I.J., Jalil J.E., Tan L.B., Cho K., Weber K.T., Clark W.A. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989 Sep, 65(3):657-670.
41. Kudej R.K., Iwase M., Uechi M., Vatner D.E., Oka N., Ishikawa Y., et al. Effects of chronic beta-adrenergic receptor stimulation in mice. J Mol Cell Cardiol 1997 Oct, 29(10):2735-2746.
42. Lau Y.H., Robinson R.B., Rosen M.R., Bilezikian J.P. Subclassification of beta-adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. Circ Res 1980 Jul, 47(1):41-48.
43. Leicht M., Greipel N., Zimmer H. Comitogenic effect of catecholamines on rat cardiac fibroblasts in culture. Cardiovasc Res 2000 Nov, 48(2):274-284.
44. Kim J., Eckhart A.D., Eguchi S., Koch W.J. Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J Biol Chem 2002 Aug 30, 277(35):32116-32123.
45. Turner N.A., Porter K.E., Smith W.H., White H.L., Ball S.G., Balmforth A.J. Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res 2003 Mar, 57(3):784-792.
46. de Andrade C.R., Fukada S.Y., Olivon V.C., de Godoy M.A., Haddad R., Eberlin M.N., et al. Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. Eur J Pharmacol 2006 Aug 14, 543(1-3):83-91.
47. Filippi S., Parenti A., Donnini S., Granger H.J., Fazzini A., Ledda F. alpha(1D)-adrenoceptors cause endothelium-dependent vasodilatation in the rat mesenteric vascular bed. J Pharmacol Exp Ther 2001 Mar, 296(3):869-875.
48. Rokosh D.G., Stewart A.F., Chang K.C., Bailey B.A., Karliner J.S., Camacho S.A., et al. Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C. J Biol Chem 1996 Mar 8, 271(10):5839-5843.
49. Sjaastad I., Schiander I., Sjetnan A., Qvigstad E., Bokenes J., Sandnes D., et al. Increased contribution of alpha 1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 2003 Apr, 177(4):449-458.
50. Rokosh D.G., Simpson P.C. Knockout of the a1A/C-adrenergic receptor subtype: the a1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 2002, 99(14):9474-9479.
51. Methven L., McBride M., Wallace G.A., McGrath J.C. The alpha 1B/D-adrenoceptor knockout mouse permits isolation of the vascular alpha 1A-adrenoceptor and elucidates its relationship to the other subtypes. Br J Pharmacol 2009 Sep, 158(1):209-224.
52. Myagmar B.-E., Rodrigo M.C., Swigart P.M., Simpson P.C. The alpha-1A adrenergic receptor subtype Is expressed in only a sub-population of ventricular myocytes (abstract). Circulation 2007, 116:II-184.
53. Methven L., Simpson P.C., McGrath J.C. Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes. Br J Pharmacol 2009 Dec, 158(7):1663-1675.
54. Wright C.D., Chen Q., Baye N.L., Huang Y., Healy C.L., Kasinathan S., et al. Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes. Circ Res 2008 Oct 24, 103(9):992-1000.
55. Jensen B.C., Swigart P.M., Laden M.E., DeMarco T., Hoopes C., Simpson P.C. The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. J Am Coll Cardiol 2009 Sep 22, 54(13):1137-1145.
56. Jensen B.C., Swigart P.M., De Marco T., Hoopes C., Simpson P.C. {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail 2009 Nov, 2(6):654-663.
57. Jensen B.C., Swigart P.M., Montgomery M.D., Simpson P.C. Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2010 Dec, 382(5-6):475-482.
58. Bristow M.R., Minobe W., Rasmussen R., Hershberger R.E., Hoffman B.B. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 1988 Dec, 247(3):1039-1045.
59. Bohm M., Diet F., Feiler G., Kemkes B., Erdmann E. Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 1988 Sep, 12(3):357-364.
60. Vago T., Bevilacqua M., Norbiato G., Baldi G., Chebat E., Bertora P., et al. Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res 1989 Mar, 64(3):474-481.
61. Steinfath M., Danielsen W., von der Leyen H., Mende U., Meyer W., Neumann J., et al. Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br J Pharmacol 1992 Feb, 105(2):463-469.
62. Hwang K.C., Gray C.D., Sweet W.E., Moravec C.S., Im M.J. Alpha 1-adrenergic receptor coupling with Gh in the failing human heart. Circulation 1996 Aug 15, 94(4):718-726.
63. Fowler M.B., Laser J.A., Hopkins G.L., Minobe W., Bristow M.R. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986 Dec, 74(6):1290-1302.
64. Bristow M.R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986 Sep, 59(3):297-309.
65. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982 Jul 22, 307(4):205-211.
66. Skomedal T., Borthne K., Aass H., Geiran O., Osnes J.B. Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 1997, 280(2):721-729.
67. Scholz H., Eschenhagen T., Neumann J., Stein B. Receptor-mediated regulation of cardiac contractility: inotropic effects of alpha-adrenoceptor stimulation with phenylephrine and noradrenaline in failing human hearts. Molecular and cellular mechanisms of cardiovascular regulation 1996, 317-325. Springer-Verlag, Tokyo. M. Endoh, M. Morad, H. Scholz, T. Iijima (Eds.).
68. Skomedal T., Aass H., Osnes J.B., Fjeld N.B., Klingen G., Langslet A., et al. Demonstration of an alpha adrenoceptor-mediated inotropic effect of norepinephrine in human atria. J Pharmacol Exp Ther 1985 May, 233(2):441-446.
69. Aass H., Skomedal T., Osnes J.B., Fjeld N.B., Klingen G., Langslet A., et al. Noradrenaline evokes an alpha-adrenoceptor-mediated inotropic effect in human ventricular myocardium. Acta Pharmacol Toxicol (Copenh) 1986 Jan, 58(1):88-90.
70. Rabinowitz B., Chuck L., Kligerman M., Parmley W.W. Positive inotropic effects of methoxamine: evidence for alpha-adrenergic receptors in ventricular myocardium. Am J Physiol 1975 Sep, 229(3):582-585.
71. Tohse N., Hattori Y., Nakaya H., Kanno M. Effects of alpha-adrenoceptor stimulation on electrophysiological properties and mechanics in rat papillary muscle. Gen Pharmacol 1987, 18(5):539-546.
72. Williamson A.P., Seifen E., Lindemann J.P., Kennedy R.H. The positive inotropic effect of alpha 1A-adrenoceptor stimulation is inhibited by 4-aminopyridine. Eur J Pharmacol 1996 May 23, 304(1-3):73-80.
73. Wang G.Y., Yeh C.C., Jensen B.C., Mann M.J., Simpson P.C., Baker A.J. Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol 2010 Mar, 298(3):H913-H920.
74. Endoh M., Shimizu T., Yanagisawa T. Characterization of adrenoceptors mediating positive inotropic responses in the ventricular myocardium of the dog. Br J Pharmacol 1978 Sep, 64(1):53-61.
75. Hescheler J., Nawrath H., Tang M., Trautwein W. Adrenoceptor-mediated changes of excitation and contraction in ventricular heart muscle from guinea-pigs and rabbits. J Physiol 1988 Mar, 397:657-670.
76. Tanaka H., Manita S., Matsuda T., Adachi M., Shigenobu K. Sustained negative inotropism mediated by alpha-adrenoceptors in adult mouse myocardia: developmental conversion from positive response in the neonate. Br J Pharmacol 1995 Feb, 114(3):673-677.
77. Nishimaru K., Kobayashi M., Matsuda T., Tanaka Y., Tanaka H., Shigenobu K. alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle. Am J Physiol Heart Circ Physiol 2001 Jan, 280(1):H132-H141.
78. McCloskey D.T., Rokosh D.G., O'Connell T.D., Keung E.C., Simpson P.C., Baker A.J. Alpha(1)-adrenoceptor subtypes mediate negative inotropy in myocardium from alpha(1A/C)-knockout and wild type mice. J Mol Cell Cardiol 2002 Aug, 34(8):1007-1017.
79. Simpson P., McGrath A., Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982 Dec, 51(6):787-801.
80. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha1-adrenergic response. J Clin Invest 1983, 72:732-738.
81. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res 1985 Jun, 56(6):884-894.
82. Starksen N.F., Simpson P.C., Bishopric N., Coughlin S.R., Lee W.M., Escobedo J.A., et al. Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc Natl Acad Sci USA 1986 Nov, 83(21):8348-8350.
83. Meidell R.S., Sen A., Henderson S.A., Slahetka M.F., Chien K.R. Alpha 1-adrenergic stimulation of rat myocardial cells increases protein synthesis. Am J Physiol 1986 Nov, 251(5 Pt 2):H1076-H1084.
84. Bishopric N.H., Simpson P.C., Ordahl C.P. Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. J Clin Invest 1987 Oct, 80(4):1194-1199.
85. Lee H.R., Henderson S.A., Reynolds R., Dunnmon P., Yuan D., Chien K.R. Alpha 1-adrenergic stimulation of cardiac gene transcription in neonatal rat myocardial cells. Effects on myosin light chain-2 gene expression. J Biol Chem 1988 May 25, 263(15):7352-7358.
86. Long C.S., Ordahl C.P., Simpson P.C. Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle cells. J Clin Invest 1989 Mar, 83(3):1078-1082.
87. Waspe L.E., Ordahl C.P., Simpson P.C. The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest 1990 Apr, 85(4):1206-1214.
88. Simpson P.C. Comments on "Load regulation of the properties of adult feline cardiocytes: The role of substrate adhesion" which appeared in Circ Res 58:692-705, 1986 (letter). Circ Res 1988, 62:864-866.
89. Fuller S.J., Gaitanaki C.J., Sugden P.H. Effects of catecholamines on protein synthesis in cardiac myocytes and perfused hearts isolated from adult rats. Stimulation of translation is mediated through the alpha 1-adrenoceptor. Biochem J 1990 Mar 15, 266(3):727-736.
90. Ikeda U., Tsuruya Y., Yaginuma T. Alpha 1-adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol 1991 Mar, 260(3 Pt 2):H953-H956.
91. Volz A., Piper H.M., Siegmund B., Schwartz P. Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J Mol Cell Cardiol 1991 Feb, 23(2):161-173.
92. Clark W.A., Rudnick S.J., LaPres J.J., Andersen L.C., LaPointe M.C. Regulation of hypertrophy and atrophy in cultured adult heart cells. Circ Res 1993 Dec, 73(6):1163-1176.
93. Clark W.A., Rudnick S.J., Andersen L.C., LaPres J.J. Myosin heavy chain synthesis is independently regulated in hypertrophy and atrophy of isolated adult cardiac myocytes. J Biol Chem 1994 Oct 14, 269(41):25562-25569.
94. Clark M.G., Patten G.S., Filsell O.H. Evidence for an alpha-adrenergic receptor-mediated control of energy production in heart. J Mol Cell Cardiol 1982 Jun, 14(6):313-321.
95. Yamashita N., Nishida M., Hoshida S., Igarashi J., Hori M., Kuzuya T., et al. Alpha 1-adrenergic stimulation induces cardiac tolerance to hypoxia via induction and activation of Mn-SOD. Am J Physiol 1996 Oct, 271(4 Pt 2):H1356-H1362.
96. Kitakaze M., Minamino T., Node K., Komamura K., Inoue M., Hori M., et al. Activation of ecto-5'-nucleotidase by protein kinase C attenuates irreversible cellular injury due to hypoxia and reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 1996 Sep, 28(9):1945-1955.
97. Karliner J.S., Honbo N., Epstein C.J., Xian M., Lau Y.F., Gray M.O. Neonatal mouse cardiac myocytes exhibit cardioprotection induced by hypoxic and pharmacologic preconditioning and by transgenic overexpression of human Cu/Zn superoxide dismutase. J Mol Cell Cardiol 2000 Oct, 32(10):1779-1786.
98. Wang Y., Ashraf M. Activation of alpha1-adrenergic receptor during Ca2+ pre-conditioning elicits strong protection against Ca2+ overload injury via protein kinase C signaling pathway. J Mol Cell Cardiol 1998 Nov, 30(11):2423-2435.
99. Zhu H., McElwee-Witmer S., Perrone M., Clark K.L., Zilberstein A. Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis. Cell Death Differ 2000 Sep, 7(9):773-784.
100. De Windt L.J., Lim H.W., Taigen T., Wencker D., Condorelli G., Dorn G.W., et al. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res 2000 Feb 18, 86(3):255-263.
101. Valks D.M., Cook S.A., Pham F.H., Morrison P.R., Clerk A., Sugden P.H. Phenylephrine promotes phosphorylation of Bad in cardiac myocytes through the extracellular signal-regulated kinases 1/2 and protein kinase A. J Mol Cell Cardiol 2002 Jul, 34(7):749-763.
102. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 2004 May 4, 101(18):6975-6980.
103. Laks M.M., Morady F., Swan H.J. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 1973 Jul, 64(1):75-78.
104. King B.D., Sack D., Kichuk M.R., Hintze T.H. Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension 1987 Jun, 9(6):582-590.
105. Patel M.B., Stewart J.M., Loud A.V., Anversa P., Wang J., Fiegel L., et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991 Nov, 84(5):2091-2100.
106. Stewart J.M., Patel M.B., Wang J., Ochoa M., Gewitz M., Loud A.V., et al. Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reserve. Am J Physiol 1992 Feb, 262(2 Pt 2):H331-H339.
107. Vecchione C., Fratta L., Rizzoni D., Notte A., Poulet R., Porteri E., et al. Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation 2002 Apr 9, 105(14):1700-1707.
108. Kitakaze M., Hori M., Tamai J., Iwakura K., Koretsune Y., Kagiya T., et al. Alpha 1-adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res 1987 May, 60(5):631-639.
109. Kitakaze M., Hori M., Sato H., Iwakura K., Gotoh K., Inoue M., et al. Beneficial effects of alpha 1-adrenoceptor activity on myocardial stunning in dogs. Circ Res 1991 May, 68(5):1322-1339.
110. Banerjee A., Locke-Winter C., Rogers K.B., Mitchell M.B., Brew E.C., Cairns C.B., et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 1993 Oct, 73(4):656-670.
111. Kitakaze M., Hori M., Morioka T., Minamino T., Takashima S., Sato H., et al. Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity. J Clin Invest 1994 May, 93(5):2197-2205.
112. Bankwala Z., Hale S.L., Kloner R.A. Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning. Circulation 1994 Aug, 90(2):1023-1028.
113. Tsuchida A., Liu Y., Liu G.S., Cohen M.V., Downey J.M. alpha 1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 1994 Sep, 75(3):576-585.
114. Tosaki A., Behjet N.S., Engelman D.T., Engelman R.M., Das D.K. Alpha-1 adrenergic receptor agonist-induced preconditioning in isolated working rat hearts. J Pharmacol Exp Ther 1995 May, 273(2):689-694.
115. Mitchell M.B., Meng X., Ao L., Brown J.M., Harken A.H., Banerjee A. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res 1995 Jan, 76(1):73-81.
116. Meng X., Brown J.M., Ao L., Banerjee A., Harken A.H. Norepinephrine induces cardiac heat shock protein 70 and delayed cardioprotection in the rat through alpha 1 adrenoceptors. Cardiovasc Res 1996 Aug, 32(2):374-383.
117. Meng X., Cleveland J.C., Rowland R.T., Mitchell M.B., Brown J.M., Banerjee A., et al. Norepinephrine-induced sustained myocardial adaptation to ischemia is dependent on alpha 1-adrenoceptors and protein synthesis. J Mol Cell Cardiol 1996 Sep, 28(9):2017-2025.
118. Haessler R., Kuzume K., Wolff R.A., Chien G.L., Davis R.F., Van Winkle D.M. Adrenergic activation confers cardioprotection mediated by adenosine, but is not required for ischemic preconditioning. Coron Artery Dis 1996 Apr, 7(4):305-314.
119. Cope J.T., Mauney M.C., Banks D., Binns O.A., Moore C.L., Rentz J.J., et al. Intravenous phenylephrine preconditioning of cardiac grafts from non-heart-beating donors. Ann Thorac Surg 1997 Jun, 63(6):1664-1668.
120. Meldrum D.R., Cleveland J.C., Rowland R.T., Banerjee A., Harken A.H., Meng X. Early and delayed preconditioning: differential mechanisms and additive protection. Am J Physiol 1997 Aug, 273(2 Pt 2):H725-H733.
121. Node K., Kitakaze M., Sato H., Minamino T., Komamura K., Shinozaki Y., et al. Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning. Circulation 1997 Aug 19, 96(4):1257-1265.
122. Baghelai K., Graham L.J., Wechsler A.S., Jakoi E.R. Delayed myocardial preconditioning by alpha1-adrenoceptors involves inhibition of apoptosis. J Thorac Cardiovasc Surg 1999 May, 117(5):980-986.
123. Baghelai K., Graham L.J., Wechsler A.S., Jakoi E.R. Phenylephrine induces delayed cardioprotection against necrosis without amelioration of stunning. Ann Thorac Surg 1999 Oct, 68(4):1219-1224.
124. Tejero-Taldo M.I., Gursoy E., Zhao T.C., Kukreja R.C. Alpha-adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart. J Mol Cell Cardiol 2002 Feb, 34(2):185-195.
125. Imani A., Faghihi M., Sadr S.S., Keshavarz M., Niaraki S.S. Noradrenaline reduces ischemia-induced arrhythmia in anesthetized rats: involvement of alpha1-adrenoceptors and mitochondrial K ATP channels. J Cardiovasc Electrophysiol 2008 Mar, 19(3):309-315.
126. Sebbag L., Katsuragawa M., Verbinski S., Jennings R.B., Reimer K.A. Intracoronary administration of the alpha 1-receptor agonist, methoxamine, does not reproduce the infarct-limiting effect of ischemic preconditioning in dogs. Cardiovasc Res 1996 Nov, 32(5):830-838.
127. Chan T., Dash R., Simpson P.C. An alpha-1A-adrenergic receptor subtype agonist prevents cardiomyopathy without increasing blood pressure (abstract). Circulation 2008, 118:S533.
128. Thornton J.D., Daly J.F., Cohen M.V., Yang X.M., Downey J.M. Catecholamines can induce adenosine receptor-mediated protection of the myocardium but do not participate in ischemic preconditioning in the rabbit. Circ Res 1993 Oct, 73(4):649-655.
129. Lips D.J., Bueno O.F., Wilkins B.J., Purcell N.H., Kaiser R.A., Lorenz J.N., et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 2004 Apr 27, 109(16):1938-1941.
130. Meng X., Shames B.D., Pulido E.J., Meldrum D.R., Ao L., Joo K.S., et al. Adrenergic induction of bimodal myocardial protection: signal transduction and cardiac gene reprogramming. Am J Physiol 1999 May, 276(5 Pt 2):R1525-R1533.
131. Communal C., Singh M., Menon B., Xie Z., Colucci W.S., Singh K. beta1 integrins expression in adult rat ventricular myocytes and its role in the regulation of beta-adrenergic receptor-stimulated apoptosis. J Cell Biochem 2003 May 15, 89(2):381-388.
132. Kudej R.K., Shen Y.T., Peppas A.P., Huang C.H., Chen W., Yan L., et al. Obligatory role of cardiac nerves and alpha1-adrenergic receptors for the second window of ischemic preconditioning in conscious pigs. Circ Res 2006 Nov 24, 99(11):1270-1276.
133. Bleasdale R.A., Frenneaux M.P. Prognostic importance of right ventricular dysfunction. Heart 2002 Oct, 88(4):323-324.
134. Bristow M.R., Feldman A.M., Adams K.F., Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?. J Card Fail 2003 Dec, 9(6):444-453.
135. Rodrigo M.C., Swigart P.M., Myagmar B.-E., Cha J., Zhu B.-Q., Yeh C.C., et al. Beta-blockers switch catecholamine activation of MAPKs from maladaptive beta-adrenergic p38 to adaptive alpha-1-adrenergic ERK (abstract). Circulation 2006, 114(II):101.
136. Rorabaugh B.R., Ross S.A., Gaivin R.J., Papay R.S., McCune D.F., Simpson P.C., et al. alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism. Cardiovasc Res 2005 Feb 1, 65(2):436-445.
137. Lin F., Owens W.A., Chen S., Stevens M.E., Kesteven S., Arthur J.F., et al. Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res 2001 Aug 17, 89(4):343-350.
138. Du X.J., Fang L., Gao X.M., Kiriazis H., Feng X., Hotchkin E., et al. Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol 2004 Nov, 37(5):979-987.
139. Du X.J., Gao X.M., Kiriazis H., Moore X.L., Ming Z., Su Y., et al. Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovasc Res 2006 Sep 1, 71(4):735-743.
140. Chaulet H., Lin F., Guo J., Owens W.A., Michalicek J., Kesteven S.H., et al. Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol 2006 Apr, 40(4):540-552.
141. Milano C.A., Dolber P.C., Rockman H.A., Bond R.A., Venable M.E., Allen L.F., et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994 Oct 11, 91(21):10109-10113.
142. Eckhart A.D., Duncan S.J., Penn R.B., Benovic J.L., Lefkowitz R.J., Koch W.J. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 2000 Jan 7-21, 86(1):43-50.
143. Wang B.H., Du X.J., Autelitano D.J., Milano C.A., Woodcock E.A. Adverse effects of constitutively active alpha(1B)-adrenergic receptors after pressure overload in mouse hearts. Am J Physiol Heart Circ Physiol 2000, 279(3):H1079-H1086.
144. Harrison S.N., Autelitano D.J., Wang B.H., Milano C., Du X.J., Woodcock E.A. Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active alpha1B-adrenergic receptors. Circ Res 1998, 83(12):1232-1240.
145. Zuscik M.J., Chalothorn D., Hellard D., Deighan C., McGee A., Daly C.J., et al. Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor. J Biol Chem 2001, 276(17):13738-13743.
146. Yun J., Zuscik M.J., Gonzalez-Cabrera P., McCune D.F., Ross S.A., Gaivin R., et al. Gene expression profiling of alpha(1b)-adrenergic receptor-induced cardiac hypertrophy by oligonucleotide arrays. Cardiovasc Res 2003, 57(2):443-455.
147. Ross S.A., Rorabaugh B.R., Chalothorn D., Yun J., Gonzalez-Cabrera P.J., McCune D.F., et al. The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model. Cardiovasc Res 2003, 60(3):598-607.
148. Grupp I.L., Lorenz J.N., Walsh R.A., Boivin G.P., Rindt H. Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol 1998, 275(4 Pt 2):H1338-H1350.
149. Lemire I., Ducharme A., Tardif J.C., Poulin F., Jones L.R., Allen B.G., et al. Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2001, 281(2):H931-H938.
150. Iaccarino G., Keys J.R., Rapacciuolo A., Shotwell K.F., Lefkowitz R.J., Rockman H.A., et al. Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors. J Am Coll Cardiol 2001, 38(2):534-540.
151. Jensen B., Swigart P., Laden M.-E., DeMarco T., Hoopes C., Simpson P. The alpha-1D is the predominant alpha-1-adrenergic receptor in human epicardial coronary arteries. JACC 2009, 54(13):1137-1145.
152. Tanoue A., Koshimizu T.A., Tsujimoto G. Transgenic studies of alpha(1)-adrenergic receptor subtype function. Life Sci 2002, 71(19):2207-2215.
153. Kariya T., Minatoguchi S., Ohno T., Yamashita K., Uno Y., Arai M., et al. Infarct size-reducing effect of ischemic preconditioning is related to alpha1b-adrenoceptors but not to alpha1a-adrenoceptors in rabbits. J Cardiovasc Pharmacol 1997, 30(4):437-445.
154. Meldrum D.R., Cleveland J.C., Sheridan B.C., Rowland R.T., Selzman C.H., Banerjee A., et al. Alpha-adrenergic activation of myocardial NF kappa B during hemorrhage. J Surg Res 1997, 69(2):268-276.
155. Kawai K., Qin F., Shite J., Mao W., Fukuoka S., Liang C.S. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 2004, 287(3):H1003-H1012.
156. Leinwand L.A. Sex is a potent modifier of the cardiovascular system. J Clin Invest 2003, 112(3):302-307.
157. Rodrigo M.C., Joho S., Swigart P.M., Foster E., O'Connell T.D., Grossman W., et al. The alpha-1-B adrenergic receptor subtype is required for physiological cardiac hypertrophy in normal development (abstract). Circulation 2005, 112(II):123.
158. Cavalli A., Lattion A.L., Hummler E., Nenniger M., Pedrazzini T., Aubert J.F., et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci USA 1997, 94(21):11589-11594.
159. Daly C.J., Deighan C., McGee A., Mennie D., Ali Z., McBride M., et al. A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics 2002, 9(2):85-91.
160. Hosoda C., Koshimizu T.A., Tanoue A., Nasa Y., Oikawa R., Tomabechi T., et al. Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 2005, 67(3):912-922.
161. Tanoue A., Nasa Y., Koshimizu T., Shinoura H., Oshikawa S., Kawai T., et al. The alpha1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 2002, 109(6):765-775.
162. McCloskey D.T., Turnbull L., Swigart P., O'Connell T.D., Simpson P.C., Baker A.J. Abnormal myocardial contraction in alpha(1A)- and alpha(1B)-adrenoceptor double-knockout mice. J Mol Cell Cardiol 2003, 35(10):1207-1216.
163. Rohrer D.K., Chruscinski A., Schauble E.H., Bernstein D., Kobilka B.K. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 1999, 274(24):16701-16708.
164. Kiriazis H., Wang K., Xu Q., Gao X.M., Ming Z., Su Y., et al. Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br J Pharmacol 2008, 153(4):684-692.
165. Cleveland J.C., Wollmering M.M., Meldrum D.R., Rowland R.T., Rehring T.F., Sheridan B.C., et al. Ischemic preconditioning in human and rat ventricle. Am J Physiol 1996, 271(5 Pt 2):H1786-H1794.
166. Cleveland J.C., Meldrum D.R., Rowland R.T., Cain B.S., Meng X., Gamboni-Robertson F., et al. Ischemic preconditioning of human myocardium: protein kinase C mediates a permissive role for alpha 1-adrenoceptors. Am J Physiol 1997, 273(2 Pt 2):H902-H908.
167. Loubani M., Galinanes M. alpha1-Adrenoceptors during simulated ischemia and reoxygenation of the human myocardium: effect of the dose and time of administration. J Thorac Cardiovasc Surg 2001, 122(1):103-112.
168. Loubani M., Galinanes M. Pharmacological and ischemic preconditioning of the human myocardium: mitoK(ATP) channels are upstream and p38MAPK is downstream of PKC. BMC Physiol 2002, 2:10.
169. Cabanes L., Costes F., Weber S., Regnard J., Benvenuti C., Castaigne A., et al. Improvement in exercise performance by inhalation of methoxamine in patients with impaired left ventricular function. N Engl J Med 1992, 326(25):1661-1665.
170. Zakir R.M., Folefack A., Saric M., Berkowitz R.L. The use of midodrine in patients with advanced heart failure. Congest Heart Fail 2009, 15(3):108-111.
171. ALLHAT CRG Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). [See comments]. Jama 2000, 283(15):1967-1975.
172. Davis B.R., Cutler J.A., Furberg C.D., Wright J.T., Farber M.A., Felicetta J.V., et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002, 137(5 Part 1):313-320.
173. Cohn J.N. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction. Circulation 1993, 87(6 Suppl):VI1-VI4.
174. Dhaliwal A.S., Habib G., Deswal A., Verduzco M., Souchek J., Ramasubbu K., et al. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol 2009, 104(2):270-275.
175. Tomai F., Crea F., Gaspardone A., Versaci F., Ghini A.S., De Paulis R., et al. Phentolamine prevents adaptation to ischemia during coronary angioplasty: role of alpha-adrenergic receptors in ischemic preconditioning. Circulation 1997, 96(7):2171-2177.
176. Gonzalez-Juanatey J.R., Iglesias M.J., Alcaide C., Pineiro R., Lago F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 2003, 107(1):127-131.
177. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 2003, 107(8):1100-1102.
178. Coats A.J. Heart Failure 99-the MOXCON story. Int J Cardiol 1999, 71(2):109-111.
179. Cohn J.N., Pfeffer M.A., Rouleau J., Sharpe N., Swedberg K., Straub M., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5(5):659-667.
180. Swedberg K., Bristow M.R., Cohn J.N., Dargie H., Straub M., Wiltse C., et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002, 105(15):1797-1803.
181. Bristow M.R., Krause-Steinrauf H., Nuzzo R., Liang C.S., Lindenfeld J., Lowes B.D., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004, 110(11):1437-1442.
182. Dunn-Meynell A.A., Yarlagadda Y., Levin B.E. Alpha 1-adrenoceptor blockade increases behavioral deficits in traumatic brain injury. J Neurotrauma 1997, 14(1):43-52.
183. Hiramoto T., Ihara Y., Watanabe Y. alpha-1 adrenergic receptors stimulation induces the proliferation of neural progenitor cells in vitro. Neurosci Lett 2006, 408(1):25-28.
184. Burcelin R., Uldry M., Foretz M., Perrin C., Dacosta A., Nenniger-Tosato M., et al. Impaired glucose homeostasis in mice lacking the alpha 1b-adrenergic receptor subtype. J Biol Chem 2003.
185. Sever P.S. Alpha 1-blockers in hypertension. Curr Med Res Opin 1999, 15(2):95-103.
186. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362(9377):7-13.
187. Kubo T., Azevedo E.R., Newton G.E., Parker J.D., Floras J.S. Lack of evidence for peripheral alpha(1)-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 2001, 38(5):1463-1469.
188. Hryniewicz K., Androne A.S., Hudaihed A., Katz S.D. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 2003, 108(8):971-976.
189. Van Tassell B.W., Rondina M.T., Huggins F., Gilbert E.M., Munger M.A. Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J 2008, 156(2):315-321.
190. Flesch M., Maack C., Cremers B., Baumer A.T., Sudkamp M., Bohm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999, 100(4):346-353.
191. Wallhaus T.R., Taylor M., DeGrado T.R., Russell D.C., Stanko P., Nickles R.J., et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001, 103(20):2441-2446.
192. Karle C.A., Kreye V.A., Thomas D., Rockl K., Kathofer S., Zhang W., et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001, 49(2):361-370.
193. Nakamura K., Kusano K., Nakamura Y., Kakishita M., Ohta K., Nagase S., et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002, 105(24):2867-2871.
194. Wang R., Miura T., Harada N., Kametani R., Shibuya M., Fukagawa Y., et al. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 2006, 318(1):45-52.
195. Hewett T.E., Grupp I.L., Grupp G., Robbins J. Alpha-skeletal actin is associated with increased contractility in the mouse heart. Circ Res 1994, 74(4):740-746.
196. López JE, Myagmar B-E, Simpson PC. Beta-myosin heavy chain is induced by pressure overload only in a minor sub-population of smaller cardiac myocytes (abstract). Available at , BCVS 2010 Scientific Sessions Abstract Presentations, page 44, P163. http://www.americanheart.org/presenter.jhtml?identifier=3074181.
197. Gao X.M., Wang B.H., Woodcock E., Du X.J. Expression of active alpha(1B)-adrenergic receptors in the heart does not alleviate ischemic reperfusion injury. J Mol Cell Cardiol 2000, 32(9):1679-1686.
198. Thomas S.A., Matsumoto A.M., Palmiter R.D. Noradrenaline is essential for mouse fetal development. Nature 1995, 374(6523):643-646.
199. Kobayashi K., Morita S., Sawada H., Mizuguchi T., Yamada K., Nagatsu I., et al. Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem 1995, 270(45):27235-27243.
200. Zhou Q.Y., Quaife C.J., Palmiter R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 1995, 374(6523):640-643.
201. Piller L.B., Davis B.R., Cutler J.A., Cushman W.C., Wright J.T., Williamson J.D., et al. Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 2002, 3(1):10.
202. Zambrowicz B.P., Sands A.T. Knockouts model the 100 best-selling drugs-will they model the next 100?. Nat Rev Drug Discov 2003, 2(1):38-51.
203. Perez D.M., Hwa J., Gaivin R., Mathur M., Brown F., Graham R.M. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 1996, 49(1):112-122.
204. Zhou Y.Y., Cheng H., Song L.S., Wang D., Lakatta E.G., Xiao R.P. Spontaneous beta(2)-adrenergic signaling fails to modulate L-type Ca(2+) current in mouse ventricular myocytes. Mol Pharmacol 1999, 56(3):485-493.
205. Xiao R.P., Avdonin P., Zhou Y.Y., Cheng H., Akhter S.A., Eschenhagen T., et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 1999, 84(1):43-52.
206. Tubio M.R., Fernandez N., Fitzsimons C.P., Copsel S., Santiago S., Shayo C., et al. Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form. J Biol Chem 2010, 285(20):14990-14998.
207. Birdsall N.J. Class A GPCR heterodimers: evidence from binding studies. Trends Pharmacol Sci 2010.
208. Heusch G., Baumgart D., Camici P., Chilian W., Gregorini L., Hess O., et al. alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000, 101(6):689-694.
209. Nishino Y., Masue T., Miwa K., Takahashi Y., Ishihara S., Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006, 97(4):747-751. discussion 51.
210. Krenz M., Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol 2004, 44(12):2390-2397.
211. Hoyer K., Krenz M., Robbins J., Ingwall J.S. Shifts in the myosin heavy chain isozymes in the mouse heart result in increased energy efficiency. J Mol Cell Cardiol 2007, 42(1):214-221.
212. Sakata Y., Hoit B.D., Liggett S.B., Walsh R.A., Dorn G.W. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 1998, 97(15):1488-1495.
213. Adams J.W., Sakata Y., Davis M.G., Sah V.P., Wang Y., Liggett S.B., et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998, 95(17):10140-10145.
214. Syed F., Odley A., Hahn H.S., Brunskill E.W., Lynch R.A., Marreez Y., et al. Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res 2004, 95(12):1200-1206.
215. Jalili T., Takeishi Y., Song G., Ball N.A., Howles G., Walsh R.A. PKC translocation without changes in Galphaq and PLC-beta protein abundance in cardiac hypertrophy and failure. Am J Physiol 1999, 277(6 Pt 2):H2298-H2304.
216. Ponicke K., Vogelsang M., Heinroth M., Becker K., Zolk O., Bohm M., et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998, 97(8):744-751.